Lymphoma/CLL 101: Know your Subtype. Dr. David Macdonald Hematologist, The Ottawa Hospital

Similar documents
Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: PA.CP.PHAR.307

Lymphoma: The Basics. Dr. Douglas Stewart

2010 Hematopoietic and Lymphoid ICD-O Codes - Alphabetical List THIS TABLE REPLACES ALL ICD-O-3 Codes

2012 Hematopoietic and Lymphoid ICD-O Codes - Numerical List THIS TABLE REPLACES ALL ICD-O-3 Codes

WHO Classification. B-cell chronic lymphocytic leukemia/small T-cell granular lymphocytic leukemia

Lymphoma: What You Need to Know. Richard van der Jagt MD, FRCPC

Clinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307

The Lymphomas. An overview..

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.

Indolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital

Indolent Lymphomas: Current. Dr. Laurie Sehn

Hepatic Lymphoma Diagnosis An Algorithmic Approach

Large cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s

Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint

Combinations of morphology codes of haematological malignancies (HM) referring to the same tumour or to a potential transformation

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

Aggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre

Lymphatic system component

Change Summary - Form 2018 (R3) 1 of 12

Lymphoid Neoplasms. Sylvie Freeman Department of Clinical Immunology, University of Birmingham

During past decades, because of the lack of knowledge

Small B-cell (Histologically Low Grade) Lymphoma

Overview of Cutaneous Lymphomas: Diagnosis and Staging. Lauren C. Pinter-Brown MD, FACP Health Sciences Professor of Medicine and Dermatology

Non-Hodgkin s Lymphomas Version

The 2016 updated WHO classification of lymphoid neoplasias

LYMPHOMAS an overview of some subtypes of NHLs

High grade B-cell lymphomas (HGBL): Altered terminology in the 2016 WHO Classification (Update of the 4 th Edition) and practical issues Xiao-Qiu Li,

Contents. vii. Preface... Acknowledgments... v xiii

88-year-old Female with Lymphadenopathy. Faizi Ali, MD

Michi Shinohara MD Associate Professor University of Washington/Seattle Cancer Care Alliance Dermatology, Dermatopathology

Integrated Hematopathology. Morphology and FCI with IHC

7 Omar Abu Reesh. Dr. Ahmad Mansour Dr. Ahmad Mansour

Classifications of lymphomas

LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center

Aggressive B-Cell Lymphomas

Understanding your diagnosis. Dr Graham Collins Consultant Haemtologist Oxford University Hospitals

Q&A Session Collecting Cancer Data: Hematopoietic and Lymphoid Neoplasms Thursday, November 6, 2014

WHO UPDATE ON LYMPHOMAS. Dr Priya Mary Jacob Asst Professor, Pathology.

FOLLICULARITY in LYMPHOMA

Update on the Classification of Aggressive B-cell Lymphomas and Hodgkin Lymphoma

Burkitt lymphoma. Sporadic Endemic in Africa associated with EBV Translocations involving MYC gene on chromosome 8

Lymphoma Read with the experts

Pathology #07. Hussein Al-Sa di. Dr. Sohaib Al-Khatib. Mature B-Cell Neoplasm. 0 P a g e

Lymphoma Update: Lymphoma Update: What s Likely to be New in the New WHO. Patrick Treseler, MD, PhD University of California San Francisco

Aggressive B-cell Lymphomas

NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)

What s new on the horizon in T-cell lymphoma Elaine S Jaffe National Cancer Institute, Bethesda MD

Pearls and pitfalls in interpretation of lymphoid lesions in needle biopsies

Hematopoietic Stem-Cell & Clinical Coverage Policy No: 11A-11 Bone Marrow Transplantation Amended Date: March 1, 2017 For Non-Hodgkin s Lymphoma

Low-grade B-cell lymphoma

MANAGEMENT OF LYMPHOMAS

Molecular Pathology of Lymphoma (Part 1) Rex K.H. Au-Yeung Department of Pathology, HKU

HODGKIN LYMPHOMA DR. ALEJANDRA ZARATE OSORNO HOSPITAL ESPAÑOL DE MEXICO

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas. Original Policy Date

A 64yo female with tuberculous empyema not improving on treatment: A tribute and farewell to Dr. Alphonse Kayembe

T-cell Lymphomas: Diagnosis and New Agents. Mary Jo Lechowicz Thursday, July 27 Debates and Didactics in Hematology and Oncology

Corrigenda. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (revised 4th edition): corrections made in second print run

Non-Hodgkin lymphoma

Hematopoietic Cell Transplantation for Non-Hodgkin's Lymphomas

Conduite à tenir devant une hyperlymphocytose

Aggressive NHL and Hodgkin Lymphoma. Dr. Carolyn Faught November 10, 2017

Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)

Immunopathology of Lymphoma

2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes

From Morphology to Molecular Pathology: A Practical Approach for Cytopathologists Part 1-Cytomorphology. Songlin Zhang, MD, PhD LSUHSC-Shreveport

Introduction: The Revised (4 th Edition) World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues

Common Problem Areas. WHO Classification. Defines separate diseases (entities) with their CLINICAL AGGRESSIVENESS LOW GRADE / HIGH GRADE

Differential diagnosis of hematolymphoid tumors composed of medium-sized cells. Brian Skinnider B.C. Cancer Agency, Vancouver General Hospital

癌症診療準則與核心測量 - 淋巴瘤 彰化基督教醫院內科部血液腫瘤科張正雄. Agenda

Neoplasms/Lymphoma/Leukemia

NAACCR Webinar Series 1

Disclosures. Advisory Board. Consultant. Investigator. MiRagen, Actelion, Celgene, Therakos. Mindera

Commentary on the 2008 WHO classification of mature T- and NK-cell neoplasms

Cutaneous Lymphoid Proliferations: A Comprehensive Textbook of Lymphocytic Infiltrates of the Skin

Many of the hematolymphoid disorders are derived

Aggressive B cell Lymphomas

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin s Lymphomas

Non-Hodgkin Lymphoma in Clinically Difficult Situations

LYMPHOMA DIAGNOSIS and PROGNOSIS. LC Lim Dept of Hematology Singapore General Hospital

LEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University

UNIVERSITÀ DI PISA FACOLTÀ DI MEDICINA E CHIRURGIA TESI DI LAUREA

The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:

EQA SCHEME CIRCULATION 33 EDUCATIONAL SLIDES DR GRAEME SMITH MONKLANDS DGH

3.1 Introduction. It is emphasised that not all tests are necessarily required in every case. 3.2 Taxonomic structure

Hematopoietic Stem-Cell Transplantation for Non-Hodgkin Lymphomas

Plasma cell myeloma (multiple myeloma)

Harmesh Naik, MD. GME Presentation to Family Practice Residents October 16, 2013.

Contractor Name: Novitas Solutions, Inc. Contractor Number: Contractor Type: MAC A. LCD ID Number: L35032 Status: A-Approved

Update in Lymphoma Imaging

WHO 4th ED Classification of Mature B-cell Neoplasms

155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary

Aggressive B-cell Lymphoma 2013

Low grade High grade , immune suppression chronic persistent inflammation viruses B-symptoms

Lymphoma: What You Need to Know

10/31/2017. Immunodeficiencies. Outline. Discuss EBV. Non-destructive Polymorphic Monomorphic Therapies Challenges

Primary Cutaneous CD30-Positive T-cell Lymphoproliferative Disorders

11/2/2017. Immunodeficiencies. Joo Y. Song, MD Assistant Professor of Clinical Pathology. I have no financial disclosures.

HENATOLYMPHOID SYSTEM THIRD YEAR MEDICAL STUDENTS- UNIVERSITY OF JORDAN AHMAD T. MANSOUR, MD. Parts 2 and 3

Transcription:

Lymphoma/CLL 101: Know your Subtype Dr. David Macdonald Hematologist, The Ottawa Hospital

Function of the Lymph System

Lymph Node

Lymphocytes B-cells develop in the bone marrow and influence the immune system by helping cells recognize infection. T-cells develop and mature in the thymus gland. Killer T-cells destroy viruses and cancers. Helper T-cells orchestrate an immune response. NK (natural killer) cells destroy viruses and cancers.

Increasing age is a risk factor for NHL 100 Incidence/100,000/annum 80 60 40 20 0 0-1 1-4 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85+ Age (years)

Lymphomas can present with many different clinical manifestations. Variable Severity: asymptomatic to extremely ill Time course: evolution over weeks, months, or years Systemic manifestations fever, night sweats, weight loss, anorexia, pruritis Local manifestations lymphadenopathy, splenomegaly most common any tissue potentially can be infiltrated

Lymphomas don t just arise in lymph nodes. Nodal Sites neck supraclavicular axillary groin (spleen) bone Extranodal GI tract (stomach) bone marrow liver skin head and neck

Other Complications of Lymphoma Bone marrow failure (infiltration) CNS infiltration Immune hemolysis or thrombocytopenia Compression of structures (eg spinal cord, ureters) by bulky disease Pleural/pericardial effusions, ascites

Diagnosis of Lymphoma History: Unwell Lumps/bumps Short of breath, abdominal pain/symptoms B symptoms: Fever Drenching Night Sweats Weight loss (>10% of baseline weight)

Lymphoma Types Hodgkin 1,ooo patients diagnosed each year Relative 5-year survival 85% Leading cancer age 15-29 Non-Hodgkin 8,200 new cases NHL each year Relative 5-year survival 66% but varies greatly by subtype Chronic lymphocytic leukemia - 2,200 patients diagnosed this year - 7-10 year survival for most

Distinguishing lymphomas by clinical behaviour Indolent NHL or CLL Aggressive NHL or HL Slow growth Often asymptomatic Long natural history possible Incurable with standard therapy Rapid growth Often symptomatic Fatal in months (if untreated) Potential for cure with standard therapy

Current Lymphoma Classification WHO 2016 Revision There are over 60 types of lymphoma. Hodgkin lymphoma Classical Hodgkin lymphomas (4) Nodular lymphocyte predominant Hodgkin lymphoma (1) Mature B-cell neoplasms (41 types) Mature T-cell & NK-cell neoplasms (27 types)

Hodgkin lymphoma Classical Hodgkin lymphoma 1. Nodular sclerosis classical Hodgkin lymphoma 2. Lymphocyte-rich classical Hodgkin lymphoma 3. Mixed cellularity classical Hodgkin lymphoma 4. Lymphocyte-depleted classical Hodgkin lymphoma Non-classical Hodgkin Lymphoma 5. Nodular lymphocyte-predominant Hodgkin lymphoma (low grade watch and wait)

Non Hodgkin B Cell Chronic lymphocytic leukemia/small lymphocytic lymphoma Monoclonal B-cell lymphocytosis* B-cell prolymphocytic leukemia Splenic marginal zone lymphoma Hairy cell leukemia Splenic B-cell lymphoma/leukemia, unclassifiable Splenic diffuse red pulp small B-cell lymphoma Hairy cell leukemia-variant Lymphoplasmacytic lymphoma Waldenström macroglobulinemia Monoclonal gammopathy of undetermined significance (MGUS), IgM* μ heavy-chain disease γ heavy-chain disease α heavy-chain disease Monoclonal gammopathy of undetermined significance (MGUS), IgG/A* Plasma cell myeloma Solitary plasmacytoma of bone Extraosseous plasmacytoma Monoclonal immunoglobulin deposition diseases* Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) Nodal marginal zone lymphoma Pediatric nodal marginal zone lymphoma Follicular lymphoma In situ follicular neoplasia* Duodenal-type follicular lymphoma* Pediatric-type follicular lymphoma* Large B-cell lymphoma with IRF4 rearrangement* Primary cutaneous follicle center lymphoma Mantle cell lymphoma In situ mantle cell neoplasia* Diffuse large B-cell lymphoma (DLBCL), NOS Germinal center B-cell type* Activated B-cell type* T-cell/histiocyte-rich large B-cell lymphoma Primary DLBCL of the central nervous system (CNS) Primary cutaneous DLBCL, leg type EBV+ DLBCL, NOS* EBV+ mucocutaneous ulcer* DLBCL associated with chronic inflammation Lymphomatoid granulomatosis Primary mediastinal (thymic) large B-cell lymphoma Intravascular large B-cell lymphoma ALK+ large B-cell lymphoma Plasmablastic lymphoma Primary effusion lymphoma HHV8+ DLBCL, NOS* Burkitt lymphoma Burkitt-like lymphoma with 11q aberration* High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements* High-grade B-cell lymphoma, NOS* B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma

Non Hodgkin T Cell T-cell prolymphocytic leukemia T-cell large granular lymphocytic leukemia Chronic lymphoproliferative disorder of NK cells Aggressive NK-cell leukemia Systemic EBV+ T-cell lymphoma of childhood* Hydroa vacciniforme like lymphoproliferative disorder* Adult T-cell leukemia/lymphoma Extranodal NK-/T-cell lymphoma, nasal type Enteropathy-associated T-cell lymphoma Monomorphic epitheliotropic intestinal T-cell lymphoma* Indolent T-cell lymphoproliferative disorder of the GI tract* Hepatosplenic T-cell lymphoma Subcutaneous panniculitis-like T-cell lymphoma Mycosis fungoides Sézary syndrome Primary cutaneous CD30+ T-cell lymphoproliferative disorders Lymphomatoid papulosis Primary cutaneous anaplastic large cell lymphoma Primary cutaneous γδ T-cell lymphoma Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma Primary cutaneous acral CD8+ T-cell lymphoma* Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder* Peripheral T-cell lymphoma, NOS Angioimmunoblastic T-cell lymphoma Follicular T-cell lymphoma* Nodal peripheral T-cell lymphoma with TFH phenotype* Anaplastic large-cell lymphoma, ALK+ Anaplastic large-cell lymphoma, ALK * Breast implant associated anaplastic large-cell lymphoma*

Current Lymphoma Classification

The different lymphomas originate at different levels of lymphocyte maturation.

Lymphoma: How do we figure out what type you have? Physical Exam Cardiac, respiratory, abdominal, Lymph nodes Biopsy FNA Incisional biopsy Excisional biopsy Laboratory: CBC and differential LDH (prognostic marker in NHL) ESR (important in HD) Bone marrow aspirate/biopsy Imaging: Chest X-ray Ultrasound CT scan neck/ chest/ abdomen/pelvis Gallium Scan PET Other: LP if CNS symptoms, or in certain high risk cases of aggressive lymphoma (sinus, testicle, bone marrow)

Pathology remains the absolute most critical piece of the diagnostic workup.

Biopsies are Examined to Classify the Lymphoma

Lymphoma Classification Morphology Immunohistochemistry Cytogenetics (gene expression profiling)

Staging of Lymphoma and CLL Stage might influence prognosis Stage might influence how we choose to treat But we DO NOT USE the term metastatic

"A" means that you have no B symptoms "B" reported fever, night sweats, & weight loss = B symptoms "E" parts of your body other than the lymph nodes are involved

CLL Staging Rai Staging System Rai stage Risk lymphocytes RBC Platelets Lymph nodes enlarged? 0 low high normal normal no no 1 intermediate high normal normal yes no 2 intermediate high normal normal maybe yes Spleen enlarged? 3 high high low normal maybe maybe 4 high high low low maybe maybe

With all of the information we are now able to formulate a treatment plan and discuss prognosis. Initial Evaluation: Specific Histologic Sub-type Extent of disease General health status of patient Treatment Plan Prognosis

Many lymphoma subtypes with different treatments and different outcomes. It is important you know exactly what your diagnosis is. If you don t know, ask your doctor.

Know Your Subtype Is it Hodgkin or Non Hodgkin? If it is Hodgkin, is it Classic or not? If it is Non Hodgkin, is it T-cell or B-cell If it is T-cell, is it Skin (Cutaneous) or Body (Systemic) If it is B-cell, is it Indolent or Aggressive

Treating lymphomas according to subtype Indolent NHL or CLL Slow growth Often asymptomatic Long natural history possible Incurable with standard therapy Watch and Wait if no symptoms Goal of treatment intitially is to get long remission without too many side effects More difficult to treat each time it comes back Goal of later treatment is to control disease symptoms

Treating lymphomas according to subtype Aggressive NHL or HL Treat right away Goal of initial treatment is to try to cure More toxic treatments may be necessary Not everyone will be cured Rapid growth Often symptomatic Fatal in months (if untreated) Potential for cure with standard therapy